We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Valneva SE | NASDAQ:VALN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.64 | -7.24% | 8.20 | 8.19 | 8.80 | 8.43 | 8.20 | 8.43 | 4,526 | 21:00:01 |
From May 2023 to May 2024
By Maitane Sardon
Shares in Valneva plunged in early trading Monday after the French biotech company said the U.S. Food and Drug Administration has delayed the target date for completing the regulatory review of the marketing application for its Chikungunya vaccine candidate.
At 0713 GMT, shares were down 8.5% at EUR6.14 after falling as much as 12% at open.
The review is now set for the end of November and not the end of August as initially planned, Valneva said.
The FDA extended the date to allow sufficient time to align and agree on the Phase 4 trial program required under the accelerated approval pathway, the company said.
The agency hasn't requested any additional clinical data for the approval process, Valneva added.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
August 14, 2023 03:40 ET (07:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Valneva Chart |
1 Month Valneva Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
